ArticleMolecular medicine reports2018
COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 147 citations in OpenAlex.
- The dual-enhanced graph learning framework DePass allows paired data integration in single-cell and spatial multiomics.Nature cell biology · 2026Article
- Observational
- Article
- Inference of secreted protein signaling activities in intercellular communication.Nature methods · 2026Article
- COL1A1-induced LOXL2 promotes ovarian cancer metastasis via a feedback loop upon inhibiting EGFR lysosomal degradation.Experimental & molecular medicine · 2026Article
- PreTSA: computationally efficient modeling of temporal and spatial gene expression patterns.Genome biology · 2026Article
- Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma.EMBO molecular medicine · 2026Article
- ISX promotes tumor migration and invasion in lung cancer by upregulating COL1A1Molecular medicine reports · 2026Article
- ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1.Frontiers in oncology · 2026Article
- Electrochemical Tracking of Macrophage Migration Inhibitory Factor: A Leap Toward Precision Colorectal Cancer Diagnosis and Prognosis.Biosensors · 2025Article
- WNT signaling in cancer: molecular mechanisms and potential therapies.Molecular biomedicine · 2025Review
- COL1A1 drives tumor progression in kidney renal clear cell carcinoma by regulating EMT through the PI3K/Akt pathway.Cancer cell international · 2025Article
- StereoMM: a graph fusion model for integrating spatial transcriptomic data and pathological images.Briefings in bioinformatics · 2025Article
- Organotropic metastasis in colorectal cancer: integrating molecular pathways with therapeutic opportunities.Frontiers in immunology · 2025Review
- Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.Protein and peptide letters · 2025Article
- Article
- CTHRC1: a key player in colorectal cancer progression and immune evasion.Frontiers in immunology · 2025Review
- PTTM: dissecting the profile of tumor tissue microbiome to reveal microbiota features and associations with host transcriptome.Briefings in bioinformatics · 2024Article
- Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics.NPJ precision oncology · 2024Article
- The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma.Journal of proteome research · 2024Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third leading cause of cancer‑associated mortality, and is a major health problem. Collagen type I α 1 (COL1A1) is a major component of collagen type I. Recently, it was reported to be overexpressed in a variety of tumor tissues and cells. However, the function of COL1A1 in CRC remains unclear. Herein, the present study demonstrated that COL1A1 was upregulated in CRC tissues and the paired lymph node tissues. Transwell assays showed that COL1A1 promoted CRC cell migration in vitro. Moreover, it was revealed that COL1A1 levels were correlated with those of WNT/planar cell polarity (PCP) signaling pathway genes; inhibition of COL1A1 decreased the expression levels of Ras‑related C3 botulinum toxin substrate 1‑GTP, phosphorylated‑c‑Jun N‑terminal kinase, and RhoA‑GTP, all of which are key genes in the WNT/PCP signaling pathway. These results may indicate the mechanisms underlying the oncogenic role of COL1A1 in CRC. In summary, the present data indicated that COL1A1 may serve as an oncoprotein, and that it may be used as a potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.